RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Adam R Wolfe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Arkansas for Medical Sciences, The Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, USA. Hauptthemen laut MEDLINE: MicroRNAs, Radiation Tolerance, Pancreatic Neoplasms, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Oncogenic RAS and RAF signaling has been implicated in contributing to radioresistance in pancreatic and thyroid cancers. In this study, we sought to better clarify molecular mechanisms contributing to this effect. We discovered that miRNA 296-3p (miR-296-3p) is significantly correlated with radiosensitivity in a panel of pancreatic cancer cells, and miR-296-3p is highly expressed in normal cells, but low in cancer cell lines. Elevated expression of miR-296-3p increases radiosensitization while decreasing the expression of the DNA repair enzyme RAD18 in both pancreatic and thyroid cancer cells. RAD18 is overexpressed in both pancreatic and thyroid tumors compared to matched normal controls, and high expression of RAD18 in tumors is associated with poor prognostic features. Modulating the expression of mutant KRAS in pancreatic cancer cells or mutant BRAF in thyroid cancer cells demonstrates a tight regulation of RAD18 expression in both cancer types. Depletion of RAD18 results in DNA damage and radiation-induced cell death. Importantly, RAD18 depletion in combination with radiotherapy results in marked and sustained tumor regression in KRAS mutant pancreatic cancer orthotopic tumors and BRAF mutant thyroid heterotopic tumors. Overall, our findings identify a novel coordinated RAS/RAF-miR-296-3p-RAD18 signaling network in pancreatic and thyroid cancer cells, which leads to enhanced radioresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The University of Arkansas for Medical Sciences, The Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, USA.
- Department of Radiation Oncology, City of Hope, Duarte, CA, USA.
- Department of Veterinary Medicine, The University of Arkansas for Medical Sciences, The Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, USA.
- Department of Radiation Oncology, City of Hope, Duarte, CA, USA. Electronic address: terwilliams@coh.org.
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- National Cancer Institute
- American Cancer Society
Zitieren
APA
Wolfe, A. R., Feng, H., Zuniga, O., Rodrigues, H., Eldridge, D. E., Yang, L., Shen, C., & Williams, T. M. (2024). RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216873
Vancouver
Wolfe AR, Feng H, Zuniga O, Rodrigues H, Eldridge DE, Yang L, et al. RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216873
BibTeX
@article{Wolfe2024,
author = {Wolfe, Adam R and Feng, Haihua and Zuniga, Oscar and Rodrigues, Henrique and Eldridge, Daniel E and Yang, Linlin and Shen, Changxian and Williams, Terence M},
title = {RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216873}
}
EUVIMED